Intraocular Preure Effect of Pegaptanib (Macugen) Injection in Patient With and Without Glaucoma

Purpoe To determine if pegaptanib (Macugen) [Eyetech Pharmaceutical; Pfizer Inc, New York, New York, UA] injection caue advere intraocular preure (IOP) effect in patient with and without glaucoma. Deign Retropective chart review. Method Review of 75 eye treated with intravitreal injection of pegaptanib (0.09 ml). The effect of thee injection on IOP wa analyzed. Mot patient received prophylactic IOP-lowering medication. Reult The mean preinjection IOP baed on the firt injection of each patient wa 14 ± 3 mm Hg; at one minute potinjection, 38 ± 14 mm Hg, at three to 10 minute wa 34 ± 9 mm Hg, and at 11 to 20 minute wa 26 ±10 mm Hg, repectively. Mot patient’ IOP had ignificantly diminihed by 30 minute potinjection. Concluion Pegaptanib injection reult in a ignificant tranient rie in IOP that coniderably diminihe by 30 minute potinjection but can take up to one hour. Thi may be damaging to the optic nerve, particularly in patient with advanced glaucoma.